Amstetten

Researchers are collecting and analyzing real-world data on treatment patterns, clinical outcomes, and side effects in adults with advanced pancreatic ductal adenocarcinoma (PDAC) in Austria. The study focuses on patients with locally advanced inoperable or metastatic PDAC who are receiving first-line chemotherapy. This research includes individuals undergoing palliative treatment to better understand how these treatments work in everyday clinical practice. Participants receive various approved chemotherapy drugs from the second line of treatment after progression on first-line therapies such as platinum- or gemcitabine-based chemotherapy or nal-Irinotecan/5-FU/Leukovorin when previously treated. The study plans to include 1500 adult patients and observes their treatment courses and outcomes over time, particularly focusing on those undergoing palliative second-line therapy. During the study, researchers will monitor treatment patterns, clinical results, and toxicities. The main outcome measured is the proportion of patients with locally advanced inoperable or metastatic PDAC receiving palliative second-line therapy after first-line chemotherapy progression, observed over 24 months. Patient information and treatment data will be collected prospectively or retrospectively, with consent obtained from prospective participants.